Can a platelet booster help sepsis patients? new trial launches
NCT ID NCT07595133
First seen May 19, 2026 · Last updated Jun 24, 2026 · Updated 6 times
Summary
This study tests a drug called romiplostim in 280 sepsis patients with very low platelet counts (under 50). The goal is to see if weekly injections can safely raise platelet levels and improve outcomes like survival and ICU stay length. It's an early-phase trial, so results will focus on safety and initial effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
romiplostim
What this could lead to
If it works, this could offer a new way to safely raise platelet counts in sepsis patients, potentially reducing bleeding complications and improving survival.
What could go wrong
This is an early phase 1 trial, so safety and effectiveness are not yet proven. The drug may not work as hoped or could cause unexpected side effects in critically ill patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.